RGNCY-0110 (PD26-TL07 STAT3 inhibitor)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

PD26-TL07 is a potent inhibitor of STAT3 which is closely associated to cancer development when its activation is sustained.  PD26-TL07 has significant antiproliferative activity against three cell lines (IC50 for HCT-116, SW480 and MDA-MB-2311 were 1.77+0.35 μM, 1.51+0.19 μM and 1.25+0.38 μM respectively).  PD26-TL07 also specifically and effectively inhibited STAT3 phosphorylation with little effect on other STATs.  PD26-TL07 has an anticancer effect both in vitro and in vivo.  It was demonstrated that PD26-TL07 could bind to the SH2 domain of STAT3.  these data suggest that PD26-TL07 is a potent anticancer agent targeting STAT3.

Systematic Name: N-(6-((4-chlorobenzyl)amino)-9H-purin-2-yl)benzamide 


Formula:  C19H15ClN6O

Mol Wt: 378.82 

PMID:  31254923

Tags: Cancer, small molecule, MDA-MB-231, HCT116, STAT3, RGNCY-0110, PD26-TL07, STAT, HCT-116, SW480